ME00183B - Novi postupak za deregulaciju amiloida - Google Patents

Novi postupak za deregulaciju amiloida

Info

Publication number
ME00183B
ME00183B MEP-2008-304A MEP2008304A ME00183B ME 00183 B ME00183 B ME 00183B ME P2008304 A MEP2008304 A ME P2008304A ME 00183 B ME00183 B ME 00183B
Authority
ME
Montenegro
Prior art keywords
cell
analog
epitope
app
nucleic acid
Prior art date
Application number
MEP-2008-304A
Other languages
English (en)
Inventor
Peter Birk
Martin Roland M E Biotech A/S Jensen
Klaus Gregorius Nielsen
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of ME00183B publication Critical patent/ME00183B/me

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)

Abstract

Opisani su novi postupci za borbu protiv bolesti koje karakteriše taloženje amiloida. Ovi postupci se obično oslanjaju na imunizaciju protiv amiloidogenih proteina (proteini koji doprinose stvaranju amiloida), kao što je beta amiloid (Aß). Poželjno je da se imunizacija obavlja ordiniranjem analoga svojstvenih amiloidogenih polipeptida. Naročito poželjan kao imunogen je svojstveni Aß, koji se modifi kuje uvođenjem samo jednog ili više stranih imunodominantnih i promiskuitetnih epitopa T-ćelije, uz bitno zadržavanje većine Aß epitopa B-ćelije. Opisana je takođe vakcinacija sa nukleinskom kisjelinom protiv amiloidogenih polipeptida, i vakcinacija koja koristi žive vakcine, kao i korisni postupci i načini ovih vakcinacija. Ti postupci i načini obuhvataju metode za identi fikaciju korisnih imunogenih analoga amiloidogenih proteina, postupke za dobijanje analoga i farmaceutskih formulacija, kao i fragmenata nukleinskih kisjelina, vektora, transformisanih ćelija, polipeptida i farmaceutskih formulacija.

Claims (45)

1.Postupak za in viva deregulaciju svojstvenog proteina beta amiloida (A ) ili svojstvenog prekursorskog proteina amiloida (APP) u životinji, uključujući humano biće, postupak koji se sastoji od ostvarivanja prezentacije imuno sistemu životinje imunogeno efikasne količine najmanje jednog analoga svojstvenog Aβ ili svojstvenog APP životinje, naznačen time, što se uvodi najmanje jedan izolovani strani epitop T helpera (TH epitop), pomoću umetanja, adicije, izbacivanja ili supstitucije, ili pomoću odvojenog kuplovanja na polihidroksipolimer kao osnovu nosača TH epitopa i sekvencije peptida izvedene iz Aβ ili APP, tako da imunizovanje životinje sa ovim analogom izaziva u životinji stvaranje antitela protiv svojstvenog Aβ ili svojstvenog APP, pri čemu se strani TH epitop uvodi u Aβ ili APP, kao što je shematski pokazano za epitope P2 i P30 na Slici 1, ili se strani T H epitop kupluje u polihidroksipolimer kao osnovu nosača, koji takođe nosi sekvenciju peptida izvedenu iz Aβ ili APP.
2. Postupak prema Zahtevu 1, naznačen time, što je rezultat modifikacije očuvanje bitne frakcije epitopa B-ćelije A ili APP, tako što se - uvodi najmanje jedan prvi ostatak koji ostvaruje targetiranje analoga na antigen koji prezentira ćelija (APC) ili B-limfocit, i/ili -uvodi najmanje jedan drugi ostatak koji stimuliše imuno sistem, i/ili - uvodi najmanje jedan treći ostatak koji optimizuje prezentaciju analoga imuno sistemu.
3.Postupak prema Zahtevu 2, naznačen time, što se analog modifikuje kovalentnim ili ne-kovalentnim vezivanjem za pogodne hemijske grupe u Al3, APP ili njihovoj subsekvenciji, uvođenjem kao bočne grupe prvog, i/ili drugog, i/ili trećeg ostatka.
4.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što uvođenje supstitucije, i/ili izbacivanja, i/ili umetanja, i/ili adicije aminokiseline vodi bitnom očuvanju ukupne tercijarne strukture amiloidogenog polipeptida.
5.Postupak prema bilo kome od Zahteva 2 do 7, naznačen time, što analog obuhvata dupliranje najmanje jednog epitopa B-ćelije amiloidogenog polipeptida i/ili uvođenje haptena.
6.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što je u životinji imunodominantan strani epitop T-ćelije.
7.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što je strani epitop T-ćelije promiskuitetan, kao što je strani epitop T-ćelije koji se bira između prirodnog promiskuitetnog epitopa T-ćelije i veštačke sekvencije koja vezuje MHC-11 peptid.
8.Postupak prema Zahtevu 7, naznačen time, što se prirodni epitop T-ćelije bira između epitopa anatoksina tetanusa, kao što su P2 ili P30, epitopa anatoksina difterije, epitopa hemaglutinina virusa gripa, i epitopa P. falciparum CS.
9.Postupak prema bilo kom od Zahteva 2 do 8, naznačen time, što je prvi ostatak bitno specifičan vezujući partner specifične površine antigena 8-limfocita, ili specifične površine antigena APC, kao što je hapten ili ugljeni hidrat, za koji postoji receptor na B-limfocitu ili na APC.
10.Postupak prema bilo kom od Zahteva 2 do 9, naznačen time, što se drugi ostatak bira između citokina, kao što je interferon y (IFN-y) ili njegov efikasni deo, Flt3L ili njegov efikasni deo, interleukin 1 (IL-1) ili njegov efikasni deo, interleukin 2 (IL-2) ili njegov efikasni deo, interleukin 4 (IL-4) ili njegov efikasni deo, interleukin 6 (IL-6) ili njegov efikasni deo, interleukin 12 (IL-12) ili njegov efikasni deo, interleukin 13 (IL-13) ili njegov efikasni deo, interleukin 15 (IL-15) ili njegov efikasni deo, stimulacioni faktor kolonije granulocit-makrofaga (GM-CSF) ili njegov efikasni deo, hormon, i protein toplotnog šoka, kao što je HSP70 ili njegov efikasni deo, HSC70 ili njegov efikasni deo, GRP94 ili njegov efikasni deo, i kalretikulin (CRT) ili njegov efikasni deo.
11.Postupak prema bilo kom od Zahteva 2 do 1O, naznačen time, što je treći ostatak po prirodi lipid, kao što je palmitoilna grupa, miristilna grupa, farnezilna grupa, geranil-geranilna grupa, sidrište GPI i N-acildigliceridna grupa, ili što je treći ostatak polihidroksipolimer, kao što je polisaharid.
12.Postupak prema Zahtevu 11, naznačen time, što polisaharid služi kao noseća osnova za koju se odvojeno vežu peptid izveden iz Al3 ili APP i strani epitop T-ćelije.
13.Postupak prema Zahtevu 12, naznačen time, što se peptid izveden iz Al3 ili APP i strani epitop T-ćelije vezuju za polisaharid preko amidne veze.
14.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što je svojstveni Al3 ili APP tako modifikovan da se očuvaju epitopi B-ćelije koji nisu izloženi vanćelijskoj fazi, kada se prezentuju u obliku vezanom za ćeliju svojstvenog APP.
15.Postupak prema Zahtevu 14, naznačen time, što se amiloidogeni polipeptid tako modifikuje da mu nedostaje najmanje jedan epitop B-ćelije koji je izložen vanćelijskoj fazi, kada se prezentuje u obliku vezanom za ćeliju svojstvenog APP.
16.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što se sastoji od supstitucije najmanje jedne sekvencije aminokiselina unutar svojstvenog Al3 ili APP sa sekvencijom aminokiselina jednake ili različite dužine, koja tom analogu daje strani epitop TH·
17.Postupak prema bilo kom od Zahteva, naznačen time, što analog sadrži sekvenciju aminokiselina koja odgovara aminokiselinama 672-714 u SEQ ID NO: 2, pri čemu umetnuta sekvencija aminokiselina daje analogu strani epitop TH, ili što analog sadrži sekvenciju aminokiselina koja odgovara aminokiselinama 672-714 u SEQ ID NO: 2, pri čemu se najmanje jedna sekvencija aminokiselina supstituiše sekvencijom jednake ili različite dužine, tako da daje strani epitop TH·
18.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što se prezentacija imuno sistemu ostvaruje tako što se najmanje dve kopije analoga kovalentno ili ne-kovalentno vezuju za molekul nosača koji je u stanju da ostvari prezentaciju višestrukih kopija antigenskih determinanti
19.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što se analog formuliše sa adjuvantom koji olakšava raskidanje autotolerancije prema auto-antigenima.
20.Postupak prema bilo kom od prethodnih Zahteva, naznačen time, što efikasna količina analoga ordinira životinji putem koji se bira između parenteralnog puta, kao što su intrakutani, subkutani i intramuskularni putevi; peritonealnog puta; oralnog puta; bukalnog puta; sublingvalnog puta; epiduralnog puta; spinalnog puta; analnog puta i intrakranijalnog puta.
21.Postupak prema Zahtevu 20, naznačen time, što je efikasna količina analoga između 0,5 !Jg i 2000 !Jg.
22.Postupak prema Zahtevu 20 ili 21, naznačen time, što se analog nalazi u uređaju virtuelnog limfnog čvora (VLN).
23.Postupak prema bilo kom od Zahteva 1 do 17, naznačen time, što se prezentacija modifikovanog amiloidogenog polipeptida imuno sistemu ostvaruje uvođenjem nukleinske kiseline (ili kiselina) koja kodira analog u ćelije životinje, čime se dobija da ćelije in vivo izlučuju uvedenu nukleinsku kiselinu (ili kiseline).
24.Postupak prema Zahtevu 23, naznačen time, što se uvedena nukleinska kiselina (ili kiseline) bira između ogoljene DNA, DNA formulisane sa naelektrisanim ili nenaelektrisanim lipidima, DNA formulisane u lipozome, DNA uključene u vektor virusa, DNA formulisane sa proteinom ili polipeptidom koji olakšava transfekciju, DNA formulisane sa targetiranim proteinom ili polipeptidom, DNA formulisane sa agensima za taloženje kalcijuma, DNA kuplovane u molekul inertnog nosača, DNA enkapsulirane u hitin ili hitosan i DNA formulisane sa adjuvantom.
25.Postupak prema Zahtevu 24, naznačen time, što se nukleinska kiselina (ili kiseline) nalazi u uređaju VLN.
26.Postupak prema bilo kom od Zahteva 20 do 25, naznačen time, što se sastoji od najmanje jednog ordiniranja/uvođenja godišnje, kao što je najmanje 2, najmanje 3, najmanje 4, najmanje 6 i najmanje 12 ordiniranja/uvođenja.
27.Postupak za tretiranje i/ili prevenciju i/ili ublažavanje Alzheimer-ove bolesti ili drugih bolesti i stanja koje karakterišu naslage A . naznačen time, što se taj postupak sastoji u deregulaciji svojstvenog A ili APP, u skladu sa postupkom bilo kog od zahteva 1 do 26, do te mere da se ukupna količina amiloida smanjuje, ili da se smanjuje brzina stvaranja amiloida, sa kliničkim značajem.
28.Analog amiloidogenog polipeptida koji se izvodi iz Af) ili APP životinje, naznačen time, što se uvodi najmanje jedan izolovani strani THepitop, kao što je shematski pokazano za epitope P2 i P30 na Slici 1, ili što se kupiuje najmanje jedan strani TH epitop na polihidroksipolimer kao osnovu nosača, koji takođe nosi sekvenciju peptida izvedenu iz A f) ili APP, tako da imunizacija životinje sa analogom izaziva stvaranje antitela protiv amiloidogenog polipeptida.
29.Analog prema Zahtevu 28, naznačen time, što je modifikacija definisana u bilo kom od Zahteva 2-17.
30.lmunogeni preparat, naznačen time, što se sastoji od imunogeno efikasne količine analoga prema Zahtevu 28 ili 29, a preparat još sadrži farmaceutski i imunološki prihvatljiv nosač, i/ili tečni nosač i opciono adjuvant.
31.Fragment nukleinske kiseline, naznačen time, što kodira analog prema Zahtevu 28 ili 29.
32.Vektor, naznačen time, što nosi fragment nukleinske kiseline prema Zahtevu 31, kao što je vektor koji je sposoban za autonomnu replikaciju.
33.Vektor prema Zahtevu 32, naznačen time, što se bira iz grupe koju čine plazmid, faga, kosmid, minohromozom i virus.
34.Vektor prema bilo kom od Zahteva 32 ili 33, naznačen time, što u smeru 5'_,3' i u operabilnoj vezi sadrži promoter za izazivanje izlučivanja fragmenta nukleinske kiseline prema Zahtevu 31, opciono sekvencije nukleinske kiseline koja kodira vodeći peptid koji omogućava izlučivanje ili integraciju u membranu polipeptidnog fragmenta, fragment nukleinske kiseline prema Zahtevu 31, opciono terminator.
35.Vektor prema bilo kom od Zahteva 32 do 34, naznačen time, što je, kada se uvede u ćeliju domaćina, u stanju ili nije u stanju da se integriše u genom ćelije domaćina.
36.Vektor prema Zahtevu 34 ili 35, naznačen time, što promoter izaziva izlučivanje u eukariotsku ćeliju i/ili u prokariotsku ćeliju.
37.Transformisana ćelija, naznačena time, što nosi vektor prema bilo kom od Zahteva 32 do 36, kao što je transformisana ćelija koja je u stanju da replicira fragment nukleinske kiseline prema Zahtevu 31.
38.Transformisana ćelija prema Zahtevu 37, naznačena time što predstavlja mikroorganizam koji se bira između bakterije, kvasca, protozoe, ili ćelije izvedene iz višećelijskog organizma koji se bira između gljivice, ćelije insekta, kao što je s2 ili SF ćelija, ćelije biljke i ćelije sisara.
39.Transformisana ćelija prema Zahtevu 37 ili 38, naznačena time, što izlučuje fragment nukleinske kiseline prema Zahtevu 31, kao što je transformisana ćelija koja na njenoj površini izlučuje ili nosi analog prema Zahtevu 28 ili 29.
40.Postupak prema bilo kom od zahteva 1-17, naznačen time, što se prezentacija imuno sistemu ostvaruje ordiniranjem ne-patogenog mikroorganizma ili virusa, koji nosi fragment nukleinske kiseline koji kodira i izlučuje analog.
41.Preparat za izazivanje stvaranja antitela protiv A ili APP, naznačen time, što taj preparat sadrži: -fragment nukleinske kiseline prema Zahtevu 31 ili vektor prema bilo kom od Zahteva 32 do 36, i - farmaceutski i imunološki prihvatljiv nosač, i/ili tečni nosač, i/ili adjuvant.
42.Stabilan ćelijski soj koji nosi vektor prema bilo kom od Zahteva 32-36, i koji izlučuje fragment nukleinske kiseline prema Zahtevu 31, i koji opciono na njegovoj površini izlučuje ili nosi analog prema Zahtevu 28 ili 29.
43.Postupak za dobijanje ćelije prema bilo kom od Zahteva 37 do 39, naznačen time, što se taj postupak sastoji od transformisanja ćelije domaćina sa fragmentom nukleinske kiseline prema Zahtevu 31 ili sa vektorom prema bilo kom od Zahteva 32 do 36.
44.Upotreba analoga prema Zahtevu 28 ili 29 za dobijanje imunogenog preparata, koji opciono sadrži adjuvant, za deregulaciju amiloida u životinji.
45.Upotreba analoga prema Zahtevu 28 ili 29 za dobijanje imunogenog preparata, koji opciono sadrži adjuvant, za tretman, profilaksu ili ublažavanje Alzheimer-ove bolesti ili drugih stanja koja karakterišu naslage amiloida.
MEP-2008-304A 2000-02-21 2001-02-19 Novi postupak za deregulaciju amiloida ME00183B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000265 2000-02-21
PCT/DK2001/000113 WO2001062284A2 (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid

Publications (1)

Publication Number Publication Date
ME00183B true ME00183B (me) 2011-02-10

Family

ID=8159174

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-304/08A MEP30408A (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid
MEP-2008-304A ME00183B (me) 2000-02-21 2001-02-19 Novi postupak za deregulaciju amiloida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-304/08A MEP30408A (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid

Country Status (29)

Country Link
US (3) US20030086938A1 (me)
EP (2) EP1632242A3 (me)
JP (1) JP5025871B2 (me)
CN (1) CN1279971C (me)
AR (1) AR027947A1 (me)
AT (1) ATE306933T1 (me)
BR (1) BR0108566A (me)
CO (1) CO5280094A1 (me)
DE (1) DE60114157T2 (me)
DK (1) DK1259251T3 (me)
EA (1) EA008762B1 (me)
EE (1) EE200200444A (me)
EG (1) EG25830A (me)
ES (1) ES2248283T3 (me)
GC (1) GC0000355A (me)
HK (1) HK1054865B (me)
HU (1) HUP0300067A3 (me)
IL (3) IL150066A0 (me)
IS (1) IS6446A (me)
ME (2) MEP30408A (me)
MY (1) MY131826A (me)
NO (1) NO20023961L (me)
NZ (1) NZ521442A (me)
PL (1) PL204878B1 (me)
RS (1) RS51164B (me)
SI (1) SI1259251T1 (me)
SK (1) SK287468B6 (me)
WO (1) WO2001062284A2 (me)
ZA (1) ZA200204830B (me)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60121729T2 (de) * 2001-04-19 2007-11-29 Dr. Hermann Schätzl Prion Proteindimere für Impfungen
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP2007300856A (ja) * 2006-05-11 2007-11-22 Hiroshi Mori アミロイドタンパク質模倣物
WO2008040759A1 (en) * 2006-10-03 2008-04-10 Pharmexa A/S Method for down-regulation of cripto
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2583978T3 (pl) * 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
US8491890B2 (en) 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CN101858910B (zh) * 2010-03-25 2013-03-27 辽宁大学 一种在蛋白质水平精确定量检测抗朊病毒药物作用效果的方法
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
US12156912B2 (en) 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
UA130246C2 (uk) 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
WO2017197253A2 (en) * 2016-05-12 2017-11-16 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
CN106854233B (zh) * 2017-03-03 2020-07-17 国家纳米科学中心 一种类肽及其制备方法和应用
CN107412782B (zh) * 2017-04-27 2020-09-08 国家纳米科学中心 一种多肽聚合物纳米材料及其制备方法和应用
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
AU2019253193B2 (en) 2018-04-10 2026-02-05 Ac Immune Sa Anti-abeta therapeutic vaccines
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
CN112210003A (zh) * 2019-07-09 2021-01-12 厦门德馨尚品医疗科技有限公司 一种重组载脂蛋白j及其类似物的晶体结构及应用
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025240977A1 (en) * 2024-05-17 2025-11-20 Board Of Regents, The University Of Texas System Compositions of sulfonyl-purine compounds and use thereof for modifying functional protein sites

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) * 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) * 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5278056A (en) * 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5192688A (en) * 1988-08-15 1993-03-09 Switzer Iii Robert C Histological analysis method
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5747323A (en) * 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE69435171D1 (de) * 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5854469A (en) * 1996-06-28 1998-12-29 Gabay; David Heating unit for therapeutic instrument
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
IT1293511B1 (it) * 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
HUP0103578A3 (en) * 1998-09-15 2005-11-28 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
SK4272001A3 (en) * 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
EP1237930B1 (en) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
AU2001274873B2 (en) * 2000-05-22 2006-10-05 New York University Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030185845A1 (en) * 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20040091945A1 (en) * 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease

Also Published As

Publication number Publication date
MEP30408A (en) 2010-10-10
MY131826A (en) 2007-09-28
SK287468B6 (sk) 2010-10-07
EP1259251B1 (en) 2005-10-19
IL150066A0 (en) 2002-12-01
PL362889A1 (en) 2004-11-02
EG25830A (en) 2012-09-02
IS6446A (is) 2002-06-26
SK11782002A3 (sk) 2004-02-03
DK1259251T3 (da) 2006-03-06
ES2248283T3 (es) 2006-03-16
WO2001062284A2 (en) 2001-08-30
GC0000355A (en) 2007-03-31
EA200200889A1 (ru) 2003-02-27
NO20023961D0 (no) 2002-08-20
NZ521442A (en) 2003-09-26
EP1632242A3 (en) 2011-08-31
ZA200204830B (en) 2003-11-26
YU57702A (sh) 2005-09-19
IL150066A (en) 2009-02-11
CO5280094A1 (es) 2003-05-30
EP1259251A2 (en) 2002-11-27
HK1054865A1 (en) 2003-12-19
JP5025871B2 (ja) 2012-09-12
HK1054865B (zh) 2007-06-01
JP2003523402A (ja) 2003-08-05
CN1416350A (zh) 2003-05-07
HUP0300067A2 (en) 2003-05-28
IL189646A0 (en) 2011-07-31
BR0108566A (pt) 2002-11-19
DE60114157T2 (de) 2006-06-29
US20070041945A1 (en) 2007-02-22
PL204878B1 (pl) 2010-02-26
US20090311281A1 (en) 2009-12-17
DE60114157D1 (de) 2006-03-02
ATE306933T1 (de) 2005-11-15
HUP0300067A3 (en) 2010-03-29
RS51164B (sr) 2010-10-31
AR027947A1 (es) 2003-04-16
EA008762B1 (ru) 2007-08-31
NO20023961L (no) 2002-08-20
EE200200444A (et) 2003-12-15
US20030086938A1 (en) 2003-05-08
CN1279971C (zh) 2006-10-18
WO2001062284A3 (en) 2001-11-29
EP1632242A2 (en) 2006-03-08
SI1259251T1 (sl) 2006-04-30

Similar Documents

Publication Publication Date Title
ME00183B (me) Novi postupak za deregulaciju amiloida
JP2003523402A5 (me)
JP2003506325A5 (me)
KR100877258B1 (ko) 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
CA2457140A1 (en) Beta-amyloid-analogue - t-cell epitope vaccine
JP5942296B2 (ja) 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用
HRP20010900A2 (en) Method for down-regulating gdf-8 activity
US20250262286A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
US6537552B1 (en) Vaccine adjuvant
WO2013067652A1 (en) Facilitator-dna combination vaccine
KR100773390B1 (ko) 단순 포진 바이러스 백신 키트
JP4382163B2 (ja) ターゲッティング分子を用いた免疫応答の増強
AU2005220156B2 (en) Peptides of IL1 beta and TNF alpha and method of treatment using same
US6867000B2 (en) Method of enhancing immune responses to herpes
Lei et al. CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal
AU700104B2 (en) Prolactin as a vaccine adjuvant
WO2004024183B1 (en) Immunization against autologous ghrelin
US20220218806A1 (en) Peptides and conjugates for treatment of arthritis
Chen Novel cancer vaccines
KR20050052499A (ko) 자가 그렐린에 대한 면역화
Apostolopoulos Peptides and Peptide Mimetics: Can they be used for tumour immunotherapy?
JP2002179700A (ja) イヌ卵透明帯ｃｚｐａタンパクのアミノ末端から＃５０−６７のアミノ酸配列を有する合成ペプチドによる避妊ワクチン。
AU2011213784A1 (en) Peptides of IL1 BETA and TNF and method of treatment using same